Speciality Medicines Peer Comparison
BSE: 544738
₹153.00
₹0.00 (0.00%)As on 17-Nov-2026IST
Market cap
₹134 Cr
Revenue (TTM)
₹75 Cr
P/E Ratio
10.3
P/B Ratio
1.9
Div. Yield
0 %
| Speciality Medicines | Entero Health | Bio Medica Laboratories | VijayPD Ceutical | Goldline Pharmaceutical | |
|---|---|---|---|---|---|
Market cap (₹ Cr) |
134 | 8,646 | 186 | 121 | 28 |
Revenue (₹ Cr) |
75 | 7,644 | 43 | 100 | 31 |
Net Profit (₹ Cr) |
13.03 | 191.80 | 11.89 | 5.00 | 4.12 |
Net Margin (%) |
17.12 | 2.50 | 27.57 | 4.79 | 13.20 |
RoE (%) |
25.60 | 8.35 | 57.64 | 9.53 | 39.41 |
Price to Earnings |
10.31 | 62.04 | 15.82 | 24.25 | 6.76 |
Price-To-Book |
1.89 | 4.87 | 2.53 | 2.31 | 1.16 |
Income Statement (₹ Cr)
| Speciality Medicines | Entero Health | Bio Medica Laboratories | VijayPD Ceutical | Goldline Pharmaceutical | |
|---|---|---|---|---|---|
|
Operating Revenue
|
75.29 | 6,591.21 | 43.09 | 100.23 | 31.20 |
|
Total Income
|
76.11 | 6,610.45 | 43.11 | 104.35 | 31.20 |
|
Total Expenditure
|
61.60 | 6,325.26 | 23.11 | 95.56 | 24.12 |
|
EBITDA
|
13.68 | 265.96 | 19.98 | 4.67 | 7.08 |
|
Depreciation
|
0.17 | 43.29 | 1.16 | 0.65 | 0.24 |
|
EBIT
|
13.51 | 222.66 | 18.81 | 4.02 | 6.84 |
|
Interest
|
1.32 | 54.39 | 2.58 | 1.66 | 1.46 |
|
Other Income
|
0.83 | 19.24 | 0.02 | 4.12 | 0.00 |
|
Exceptional Items
|
-- | -8.18 | -- | -0.01 | -- |
|
Profit before Tax
|
13.02 | 179.34 | 16.25 | 6.47 | 5.39 |
|
Provision for Tax
|
-0.01 | 33.50 | 4.37 | 1.47 | 1.27 |
|
Profit after Tax
|
13.03 | 145.84 | 11.89 | 5.00 | 4.12 |
Liabilities (₹ Cr)
| Speciality Medicines | Entero Health | Bio Medica Laboratories | VijayPD Ceutical | Goldline Pharmaceutical | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
71.19 | 1,688.61 | 26.51 | 52.48 | 14.25 |
|
Minority Interest
|
-- | 63.94 | -6.17 | -0.08 | -- |
|
Non-Current Liabilities
|
5.15 | 206.12 | 33.45 | 4.66 | 2.43 |
|
Current Liabilities
|
18.88 | 1,587.57 | 19.18 | 42.23 | 12.11 |
|
Total Liabilities
|
95.22 | 3,600.22 | 73.31 | 99.64 | 28.87 |
Assets (₹ Cr)
| Speciality Medicines | Entero Health | Bio Medica Laboratories | VijayPD Ceutical | Goldline Pharmaceutical | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
6.26 | 1,037.80 | 18.31 | 23.77 | 2.75 |
|
Current Assets
|
88.97 | 2,503.13 | 54.67 | 75.53 | 26.05 |
|
Total Assets
|
95.22 | 3,600.22 | 73.31 | 99.64 | 28.87 |
|
Total Debt*
|
6.64 | 566.68 | 39.99 | 36.71 | 9.16 |
|
Net Current Assets
|
70.09 | 915.56 | 35.48 | 33.30 | 13.93 |
|
Contingent Liabilities
|
-- | 5.51 | -- | 0.14 | 3.37 |
Cashflow (₹ Cr)
| Speciality Medicines | Entero Health | Bio Medica Laboratories | VijayPD Ceutical | Goldline Pharmaceutical | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-1.28 | 96.20 | -6.03 | -8.61 | 2.81 |
|
Cash Flow from Investing Activities
|
-2.83 | -303.06 | -2.31 | -13.33 | -0.06 |
|
Cash from Financing Activities
|
27.82 | 123.66 | 8.43 | 31.59 | -3.40 |
|
Net Cash Inflow / Outflow
|
23.70 | -83.20 | 0.09 | 9.65 | -0.65 |
Ratios
Profitability Ratios
| Speciality Medicines | Entero Health | Bio Medica Laboratories | VijayPD Ceutical | Goldline Pharmaceutical | |
|---|---|---|---|---|---|
|
ROCE (%)
|
25.26 | 10.93 | 39.14 | 9.12 | 30.60 |
|
ROE (%)
|
25.60 | 8.57 | 57.64 | 9.53 | 39.41 |
|
ROA (%)
|
19.27 | 4.68 | 21.33 | 5.04 | 14.98 |
|
EBIT Margin (%)
|
19.27 | 4.33 | 46.41 | 8.77 | 22.70 |
|
Net Margin (%)
|
17.12 | 2.21 | 27.57 | 4.79 | 13.20 |
|
Cash Profit Margin (%)
|
17.54 | 2.87 | 30.29 | 5.64 | 13.97 |
Growth Ratios
| Speciality Medicines | Entero Health | Bio Medica Laboratories | VijayPD Ceutical | Goldline Pharmaceutical | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
29.20 | 29.35 | 12.45 | 0.00 | 11.20 |
|
EBIT Growth (%)
|
54.39 | 35.13 | 29.01 | -- | 16.95 |
|
Net Profit Growth (%)
|
81.11 | 35.75 | 22.50 | 0.00 | 45.26 |
|
EPS Growth (%)
|
32.67 | 21.32 | 21.40 | 0.00 | 45.26 |
|
Book Value Growth (%)
|
132.49 | -2.19 | 79.96 | 0.00 | 47.19 |
Valuation Ratios
| Speciality Medicines | Entero Health | Bio Medica Laboratories | VijayPD Ceutical | Goldline Pharmaceutical | |
|---|---|---|---|---|---|
|
Price / Earnings
|
8.49 | 47.12 | 0.00 | 25.46 | 0.00 |
|
Price / Book Value
|
1.55 | 3.22 | 0.00 | 2.43 | 0.00 |
|
Dividend Yield (%)
|
0.00 | 0.00 | -- | 0.00 | -- |
|
EV/EBITDA
|
6.39 | 20.43 | 2.45 | 16.66 | 2.44 |
|
Market Cap (₹ Cr)
|
110.62 | 5,420.61 | 0.00 | 127.33 | 0.00 |
Solvency Ratios
| Speciality Medicines | Entero Health | Bio Medica Laboratories | VijayPD Ceutical | Goldline Pharmaceutical | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.09 | 0.34 | 1.51 | 0.70 | 0.64 |
|
Short term debt to equity ratio
|
0.01 | 0.26 | 0.22 | 0.48 | 0.42 |
|
Current Ratio
|
4.71 | 1.58 | 2.85 | 1.79 | 2.15 |
|
Quick Ratio
|
3.21 | 1.05 | 0.95 | 1.49 | 1.64 |
|
Interest Coverage
|
10.87 | 4.30 | 7.29 | 4.89 | 4.70 |
Operating Efficiency Ratios
| Speciality Medicines | Entero Health | Bio Medica Laboratories | VijayPD Ceutical | Goldline Pharmaceutical | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
35.20 | 18.39 | 25.19 | 30.52 | 51.70 |
|
Asset Turnover
|
1.11 | 2.11 | 0.77 | 1.01 | 1.13 |
|
Receivable days
|
87.52 | 56.56 | 63.33 | 111.39 | 156.90 |
|
Inventory Days
|
110.76 | 41.57 | 230.85 | 45.39 | 75.99 |
|
Payable days
|
43.45 | 34.66 | 181.09 | 32.72 | 64.86 |
|
Cash Conversion Cycle
|
154.84 | 63.47 | 113.10 | 124.06 | 168.03 |